Fractionated Low-Dose Radiotherapy after Myeloablative Stem Cell Transplantation for Local Control in Patients with High-Risk Neuroblastoma

Cancer

Volumn 100, Issue 6, 2004, Pages 1268-1275

  Bradfield, Scott M ^a   Douglas, James G ^b   Hawkins, Douglas S ^a   Sanders, Jean E ^c   Park, Julie R ^a  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Adverse effects; Local neoplasm recurrence; Neuroblastoma; Radiotherapy

Indexed keywords

CARBOPLATIN; ISOTRETINOIN; MYELOABLATIVE AGENT; THIOTEPA; TOPOTECAN;

BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INFANT; INFECTION; LEG LENGTH INEQUALITY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; METASTASIS; MULTIMODALITY CANCER THERAPY; NEUROBLASTOMA; PARENT; PRIORITY JOURNAL; RADIATION BEAM; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; REVIEW; TIME; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 1542374048     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20091     Document Type: Review

References (36)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, 4th edition. Philadelphia: Lippincott, 2002:895-938.
2. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of Stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol. 2000;18:18-26.
3. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol. 1996;14:2417-2426.
4. Matthay KK, Villablanca JG, Seeger RS, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
5. Castleberry RP. Biology and treatment of neuroblastoma. Pediatr Clin North Am. 1997;44:919-937.
6. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for Stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994;12:2607-2613.
7. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol. 1993;11:2226-2233.
8. Ikeda H, August CS, Goldwein JW, Ross AJ III, D'Angio GJ, Evans AE. Sites of relapse in patients with neuroblastoma following bone marrow transplantation in relation to preparatory "debulking" treatments. J Pediatr Surg. 1992;27:1438-1441.
9. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001; 19:2821-2828.
10. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II study. J Clin Oncol. 2002;20:2284-2292.
11. Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with Stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002;24:613-621.
12. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis Stage 4 neuroblastoma. Bone Marrow Transplant. 2000;25:937-942.
13. Grupp SA, Stern JW, Bunin N, et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol. 2000;35:696-700.
14. Park JR, Slattery J, Gooley T, et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/ recurrent pediatric solid tumors. Med Pediatr Oncol. 2000;35:719-723.
15. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001;36:227-230.
16. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003;56:28-39.
17. La Quaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NK. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg. 1994;29:1162-1165.
18. Paulino AC, Mayr NA, Simon JH, Buatti JM. Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys. 2002; 52:1025-1031.
19. Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group Stage C neuroblastoma. J Clin Oncol. 1991;9:789-795.
20. Marcus KC, Tarbell NJ. The changing role of radiation therapy in the treatment of neuroblastoma. Semin Radiat Oncol. 1997;7:195-203.
21. Jacobson HM, Marcus RB, Thar TL, et al. Pediatric neuroblastoma: postoperative radiation therapy using less than 2000 rad. Int J Radiat Oncol Biol Phys. 1983;9:501-505.
22. Jacobson GM, Sause WT, O'Brien RT. Dose response analysis of pediatric neuroblastoma to megavoltage radiation. Am J Clin Oncol. 1984;7:693-697.
23. Halperin EC, Cox EB. Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984. Int J Radiat Oncol Biol Phys. 1986;12:1829-1837.
24. Kushner BH, O'Reilly RJ, Mandell LR, Gulati SC, LaQuaglia M, Cheung NK. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol. 1991;9:274-279.
25. Kremens B, Klingebiel T, Herrmann F, et al. High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma. Med Pediatr Oncol. 1994;23:470-475.
26. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
28. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of Stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998;16:1256-1264.
29. Kreissman SG, Seeger RC, Stram DO, et al. Peripheral blood stem cell (PBSC) support for multiple cycles of dose intensive chemotherapy for Stage IV neuroblastoma (NB) is feasible with little risk of tumor contamination: a Children's Cancer Group report [abstract]. Proc Am Soc Clin Oncol. 2000;19:585a.
30. Kletzel M, Abella EM, Sandler ES, et al. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a Phase I/II study of the Pediatric Blood and Marrow Transplant Consortium. J Pediatr Hematol Oncol. 1998;20:49-54.
31. Castel V, Tovar JA, Costa E, et al. The role of surgery in Stage IV neuroblastoma. J Pediatr Surg. 2002;37:1574-1578.
32. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 1992;31:229-239.
33. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J Pediatr Hematol Oncol. 1998;20:315-318.
34. Shimoni A, Korbling M. Tumor cell contamination in reinfused stem cell autografts: does it have clinical significance? Crit Rev Oncol Hematol. 2002;41:241-250.
35. Kushner BH, Cheung NK, Kramer K, Heller G, Jhanwar SC. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol. 1998;16:3880-3889.
36. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 2003;21:1074-1081.